Key result
Valve-in-valve TAVR linked to ~38% fewer 30-day major events versus redo SAVR.
Why the study?
Clinical comparison of VIV TAVR and redo SAVR for aortic bioprosthesis failure has been limited by small patient numbers.
Does VIV TAVR improve clinical outcomes compared to redo SAVR in patients with aortic bioprosthesis failure?
Cohort (n=4,327)
Yes
Does VIV TAVR improve clinical outcomes compared to redo SAVR in patients with aortic bioprosthesis failure?
Answers are grounded in this paper and cite their sources.
In a nationwide French cohort, VIV TAVR for aortic bioprosthesis failure was associated with better 30-day outcomes than redo SAVR, but similar long-term major cardiovascular outcomes despite higher rates of pacemaker implantation and heart failure rehospitalization.
BACKGROUND: Valve-in-valve (VIV) transcatheter aortic valve replacement (TAVR) and redo surgical aortic valve replacement (SAVR) represent the 2 treatments for aortic bioprosthesis failure. Clinical comparison of both therapies remains limited by the number of patients analyzed. OBJECTIVES: The purpose of this study was to analyze the outcomes of VIV TAVR versus redo SAVR at a nationwide level in France. METHODS: Based on the French administrative hospital-discharge database, the study collected information for patients treated for aortic bioprosthesis failure with isolated VIV TAVR or redo SAVR between 2010 and 2019. Propensity score matching was used for the analysis of outcomes. RESULTS: A total of 4,327 patients were found in the database. After matching on baseline characteristics, 717 patients were analyzed in each arm. At 30 days, VIV TAVR was associated with lower rates of the composite of all-cause mortality, all-cause stroke, myocardial infarction, and major or life-threatening bleeding (odds ratio: 0.62; 95% confidence interval: 0.44 to 0.88; p = 0.03). During follow-up (median 516 days), the combined endpoint of cardiovascular death, all-cause stroke, myocardial infarction, or rehospitalization for heart failure was not different between the 2 groups (odds ratio: 1.18; 95% confidence interval: 0.99 to 1.41; p = 0.26). Rehospitalization for heart failure and pacemaker implantation were more frequently reported in the VIV TAVR group. A time-dependent interaction between all-cause and cardiovascular mortality following VIV TAVR was reported (p-interaction <0.05). CONCLUSIONS: VIV TAVR was observed to be associated with better short-term outcomes than redo SAVR. Major cardiovascular outcomes were not different between the 2 treatments during long-term follow-up.
No takes yet. Share an insight, caveat, or question.
Deharo et al. (2020) conducted a cohort in Aortic bioprosthesis failure (n=4,327). Valve-in-valve (VIV) transcatheter aortic valve replacement (TAVR) vs. Redo surgical aortic valve replacement (SAVR) was evaluated on Composite of all-cause mortality, all-cause stroke, myocardial infarction, and major or life-threatening bleeding at 30 days (OR 0.62, 95% CI 0.44-0.88, p=0.03). Valve-in-valve TAVR was associated with a lower 30-day rate of mortality, stroke, MI, and bleeding compared to redo SAVR, with similar long-term outcomes.
Synapse has enriched 10 related papers. Consider them for comparative context: